Latanoprost Azad (Latanoprost)

Latanoprost binds to FP receptors in the eye’s ciliary body, triggering biochemical changes that increase the outflow of aqueous humor through the uveoscleral pathway. This enhanced drainage reduces intraocular pressure, which is the primary therapeutic goal in glaucoma management.

The dosing regimen for Latanoprost Azad is determined by the prescribing ophthalmologist. Typically, one drop is instilled into the affected eye(s) once daily in the evening, but the exact dose and timing are individualized based on patient response and clinical judgment.

The safety of latanoprost in pregnancy and lactation has not been definitively established. It is classified as pregnancy category unknown, and use should be considered only if the potential benefit justifies any potential risk to the fetus or infant. Consultation with a healthcare professional is essential.

To order Latanoprost Azad, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details, and any necessary import documentation.

Latanoprost belongs to the prostaglandin analog class, which generally offers once‑daily dosing and strong intraocular pressure reduction. Compared with beta‑blocker or carbonic anhydrase inhibitor drops, latanoprost often provides greater pressure lowering with a favorable dosing schedule, though individual response may vary.

Latanoprost Azad should be stored at room temperature, below 25 °C, in its original packaging. Protect the bottle from direct sunlight and moisture to maintain stability. Do not freeze the solution.

The medication is administered as an eye drop. The patient should wash hands, tilt the head back, pull down the lower eyelid to create a pocket, and place one drop into the eye. Close the eye gently for a few minutes and avoid blinking excessively.

Serious risks, though rare, include severe eye inflammation (uveitis or iritis), allergic reactions such as swelling or rash, sudden vision loss, and corneal edema. Any of these symptoms require immediate medical evaluation and discontinuation of the drug.

Patients with known hypersensitivity to latanoprost or any component of the formulation should avoid its use. Those with active ocular infections, severe inflammation, or a history of cystoid macular edema should consult their ophthalmologist before starting therapy.